BackSupernus Pharmaceuticals Overview

Supernus Pharmaceuticals Other Current Assets

Supernus Pharmaceuticals's other current assets is $56M.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$55.85M
77.77% YoYΔ $24.43M vs prior year quarter

Peer average / median

Loading

Supernus Pharmaceuticals Other Current Assets History

Loading

Supernus Pharmaceuticals vs. peers: Other Current Assets Comparison

Loading

Supernus Pharmaceuticals Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Supernus Pharmaceuticals (SUPN) FAQ

Supernus Pharmaceuticals (SUPN) currently reports a other current assets of $56M as of June 2026. That compares with $31M in the prior-year period — up 77.8% year over year. Use the charts on this page to explore Supernus Pharmaceuticals's other current assets history and peer comparisons.

Supernus Pharmaceuticals's other current assets increased from $31M to $56M — a 77.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Supernus Pharmaceuticals reported $56M in other current assets as of June 2026. That compares with $31M in the prior-year period — up 77.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current assets of $56M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Supernus Pharmaceuticals, and consider following SUPN for alerts when major investors trade the stock.

Supernus Pharmaceuticals is classified in the Healthcare sector. On other current assets, it currently shows $56M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SUPN with unrelated industries.